MedTrace Logo

TK-based Suicide Gene Therapy for Hepatocellular Carcinoma

NCT00844623 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether activation of a prodrug after intratumoral gene transfer is safe in humans, and to determine dose levels for further clinical development.

Conditions

  • Carcinoma, Hepatocellular

Interventions

GENETIC

TK99UN

escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally

Sponsors & Collaborators

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Jesus Prieto, MD · Clinica Universitaria de Navarra

  • Bruno Sangro, MD · Clinica Universitaria de Navarra

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2003-11-30
Completion
2008-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00844623 on ClinicalTrials.gov